FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151826254> ?p ?o ?g. }

• W2151826254 endingPage "458" @default.
• W2151826254 startingPage "447" @default.
• W2151826254 abstract "Abstract Purpose: Targeting the tumor vasculature by vascular disrupting agents (VDAs) has shown therapeutic activity in mouse models. In most cases, however, VDA efficacy is substantially compromised by the inability of these drugs to completely kill tumor cells located at the periphery of the tumor mass. In this study, we investigated anti-tumor effects of L19mTNFα, a fusion protein composed of L19 (scFv), specific for the angiogenesis-associated ED-B containing fibronectin isoform, and murine TNFα, in xenograft models of esophageal cancer. Experimental design: We evaluated ED-B expression in esophageal cancer samples. Subsequently, we generated subcutaneous xenografts from primary tumors, treated them with the L19mTNFα scFv, and determined effects on tumor vasculature, viability and proliferation, and VEGF expression and infiltration by hematopoietic cells. To overcome tumor resistance, L19mTNFα scFv was combined with vandetanib, a tyrosine kinase inhibitor of VEGF receptor, epidermal growth factor receptor, and RET signaling. Results: ED-B was broadly expressed by esophageal cancer cell lines, as well as xenografts and primary surgical samples of esophageal cancer. Administration of L19mTNFα acutely damaged tumor vasculature and increased necrosis, indicating a VDA-like activity of this immunoconjugate. This event was followed, however, by rapid tumor growth recovery associated with increased expression of VEGF and recruitment of CD11b+Gr1+ myeloid cells into tumors. Combination of L19mTNFα with vandetanib severely impaired vascular functions in tumors, leading to a reduction of cell proliferation and increased necrosis, without apparent signs of toxicity. Conclusion: These findings indicate that a combination of vascular damaging agents with anti-angiogenic drugs could represent a promising therapeutic strategy for esophageal cancer. Clin Cancer Res; 17(3); 447–58. ©2010 AACR." @default.
• W2151826254 created "2016-06-24" @default.
• W2151826254 creator A5009875698 @default.
• W2151826254 creator A5013448319 @default.
• W2151826254 creator A5019015189 @default.
• W2151826254 creator A5026589555 @default.
• W2151826254 creator A5039389370 @default.
• W2151826254 creator A5052223562 @default.
• W2151826254 creator A5053762694 @default.
• W2151826254 creator A5055470201 @default.
• W2151826254 creator A5060406994 @default.
• W2151826254 creator A5062202188 @default.
• W2151826254 date "2011-02-01" @default.
• W2151826254 modified "2023-10-16" @default.
• W2151826254 title "Vandetanib Improves Anti-Tumor Effects of L19mTNFα in Xenograft Models of Esophageal Cancer" @default.
• W2151826254 cites W1579297325 @default.
• W2151826254 cites W1966726954 @default.
• W2151826254 cites W1990711717 @default.
• W2151826254 cites W2000820465 @default.
• W2151826254 cites W2001497420 @default.
• W2151826254 cites W2001751294 @default.
• W2151826254 cites W2004682512 @default.
• W2151826254 cites W2009507555 @default.
• W2151826254 cites W2012080977 @default.
• W2151826254 cites W2017092245 @default.
• W2151826254 cites W2017322644 @default.
• W2151826254 cites W2024904424 @default.
• W2151826254 cites W2032769992 @default.
• W2151826254 cites W2033112763 @default.
• W2151826254 cites W2034982045 @default.
• W2151826254 cites W2037058615 @default.
• W2151826254 cites W2041634248 @default.
• W2151826254 cites W2046714964 @default.
• W2151826254 cites W2077729786 @default.
• W2151826254 cites W2080034938 @default.
• W2151826254 cites W2083684074 @default.
• W2151826254 cites W2098282622 @default.
• W2151826254 cites W2103763724 @default.
• W2151826254 cites W2104374675 @default.
• W2151826254 cites W2110489920 @default.
• W2151826254 cites W2111870457 @default.
• W2151826254 cites W2114940128 @default.
• W2151826254 cites W2122129320 @default.
• W2151826254 cites W2124472420 @default.
• W2151826254 cites W2136783006 @default.
• W2151826254 cites W2138539226 @default.
• W2151826254 cites W2139877124 @default.
• W2151826254 cites W2151637779 @default.
• W2151826254 cites W2165539456 @default.
• W2151826254 cites W29053622 @default.
• W2151826254 doi "https://doi.org/10.1158/1078-0432.ccr-10-1420" @default.
• W2151826254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21106730" @default.
• W2151826254 hasPublicationYear "2011" @default.
• W2151826254 type Work @default.
• W2151826254 sameAs 2151826254 @default.
• W2151826254 citedByCount "19" @default.
• W2151826254 countsByYear W21518262542012 @default.
• W2151826254 countsByYear W21518262542013 @default.
• W2151826254 countsByYear W21518262542015 @default.
• W2151826254 countsByYear W21518262542016 @default.
• W2151826254 countsByYear W21518262542017 @default.
• W2151826254 countsByYear W21518262542019 @default.
• W2151826254 countsByYear W21518262542020 @default.
• W2151826254 countsByYear W21518262542021 @default.
• W2151826254 countsByYear W21518262542022 @default.
• W2151826254 crossrefType "journal-article" @default.
• W2151826254 hasAuthorship W2151826254A5009875698 @default.
• W2151826254 hasAuthorship W2151826254A5013448319 @default.
• W2151826254 hasAuthorship W2151826254A5019015189 @default.
• W2151826254 hasAuthorship W2151826254A5026589555 @default.
• W2151826254 hasAuthorship W2151826254A5039389370 @default.
• W2151826254 hasAuthorship W2151826254A5052223562 @default.
• W2151826254 hasAuthorship W2151826254A5053762694 @default.
• W2151826254 hasAuthorship W2151826254A5055470201 @default.
• W2151826254 hasAuthorship W2151826254A5060406994 @default.
• W2151826254 hasAuthorship W2151826254A5062202188 @default.
• W2151826254 hasBestOaLocation W21518262541 @default.
• W2151826254 hasConcept C121608353 @default.
• W2151826254 hasConcept C126322002 @default.
• W2151826254 hasConcept C142724271 @default.
• W2151826254 hasConcept C167734588 @default.
• W2151826254 hasConcept C170493617 @default.
• W2151826254 hasConcept C17991360 @default.
• W2151826254 hasConcept C203014093 @default.
• W2151826254 hasConcept C2777025900 @default.
• W2151826254 hasConcept C2779013556 @default.
• W2151826254 hasConcept C2779438470 @default.
• W2151826254 hasConcept C2779742542 @default.
• W2151826254 hasConcept C2780283643 @default.
• W2151826254 hasConcept C2780333294 @default.
• W2151826254 hasConcept C2780394083 @default.
• W2151826254 hasConcept C42362537 @default.
• W2151826254 hasConcept C502942594 @default.
• W2151826254 hasConcept C71924100 @default.
• W2151826254 hasConceptScore W2151826254C121608353 @default.
• W2151826254 hasConceptScore W2151826254C126322002 @default.
• W2151826254 hasConceptScore W2151826254C142724271 @default.
• W2151826254 hasConceptScore W2151826254C167734588 @default.

• next